Sofinnova Partners led a €11m Series A round in EnginZyme.

Sofinnova Partners led a €11m Series A round in EnginZyme, the cell-free synthetic biology company, with participation from Industrifonden and SEB Greentech VC. "Sofinnova Partners brings a deep industrial experience, which makes them the perfect partner for us. This is a complex field, so it is important to have investors that can provide not only the financial support but also strategic guidance. With over a decade of experience investing in industrial biotechnology, there are few investors as well placed as Sofinnova Partners to bring this domain expertise to the table," Karim Engelmark Cassimjee, EnginZyme CEO.